Abstracts tagged "bisphosphonates and osteoporosis"

Abstract Number: 1247 • 2013 ACR/ARHP Annual Meeting
Association Between Bisphosphonate Switching Behavior and Cost Outcomes In Postmenopausal United States Veterans
Joanne Lafleur¹, Scott L. DuVall², Jeffrey R. Curtis³, Robert A Adler⁴, Tina Willson⁵, Irene Agodoa⁶, Bradley Stolshek⁷ and Richard E. Nelson⁸, ¹University of Utah College of Pharmacy, Salt Lake City, UT, ²VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, ⁵Pharmacotherapy, University of Utah, Salt Lake City, UT, ⁶Amgen Inc, Thousand Oaks, CA, ⁷Amgen, Inc., Thousand Oaks, CA, ⁸Division of Epidemiology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Many bisphosphonate-treated patients discontinue therapy within the first year. Some later restart the same or a different bisphosphonate. The implications of this on total…
Abstract Number: 1217 • 2013 ACR/ARHP Annual Meeting
Determination Of Vitamin D Level Prior To The Initiation Of Bisphosphonate Therapy
Chris T. Derk¹, Ruchika Patel², Rennie L. Rhee², Yiu Tak Leung¹, R. Michelle Koolaee², Shiv Sehra² and Ashwini Komarla³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Vitamin D deficiency is under-recognized and in 18-35% of patients who do not respond to bisphosphonates, concurrent use of vitamin D 1000 units daily…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].